Skip to content
10-Q

Quarterly Report

BRIACELL THERAPEUTICS CORP. BCTX BCTXL BCTXZ

0001493152-25-027240

← back to feed
Filed
Dec 11, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Dec 11, 2025 1.88M sh
Shares Diluted Q1 2026 · Oct 31, 2025 1.88M sh
Shares Diluted restated Q1 2026 · Oct 31, 2024 177.61K sh
Operating Cash Flow Q1 2026 · Oct 31, 2025 −$7.7M
Operating Cash Flow Q1 2026 · Oct 31, 2024 −$6.96M
Short Term Investments Q1 2026 · Oct 31, 2025 $7.46M
Short Term Investments Q1 2026 · Jul 31, 2025 $7.37M
Cash And Equivalents Q1 2026 · Oct 31, 2025 $2.71M
Cash And Equivalents Q1 2026 · Jul 31, 2025 $10.49M
Current Liabilities Q1 2026 · Oct 31, 2025 $3.32M
Current Liabilities Q1 2026 · Jul 31, 2025 $3.98M
Current Assets Q1 2026 · Oct 31, 2025 $11.35M
Current Assets Q1 2026 · Jul 31, 2025 $19.93M
Total Assets Q1 2026 · Oct 31, 2025 $13.08M
Total Assets Q1 2026 · Jul 31, 2025 $21.65M
Eps Diluted Q1 2026 · Oct 31, 2025 −$4.35
Eps Diluted restated Q1 2026 · Oct 31, 2024 −$32.67
Eps Basic Q1 2026 · Oct 31, 2025 −$4.35
Eps Basic restated Q1 2026 · Oct 31, 2024 −$32.67
Sga Expense Q1 2026 · Oct 31, 2025 $1.64M
Sga Expense Q1 2026 · Oct 31, 2024 $1.49M
Rd Expense Q1 2026 · Oct 31, 2025 $6.68M
Rd Expense Q1 2026 · Oct 31, 2024 $3.67M
Net Income Q1 2026 · Oct 31, 2025 −$8.2M
Net Income Q1 2026 · Oct 31, 2024 −$5.8M
Operating Income Q1 2026 · Oct 31, 2025 −$8.32M
Operating Income Q1 2026 · Oct 31, 2024 −$5.15M